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Background: Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are commonly loaded with 
either clopidogrel or prasugrel in addition to aspirin. This study aimed to assess the safety of reloading prasugrel in patients initially loaded with 
clopidogrel, when compared to prasugrel loading alone.
methods: The study included a cohort of 606 consecutive ACS patients who received a prasugrel 60-mg loading dose before PCI. These patients 
were categorized into clopidogrel preloading (300- or 600-mg) followed by prasugrel reloading (CP-load group, n=90) and prasugrel loading only 
(P-load group, n=516). Both groups received prasugrel 10 mg as maintenance dose following PCI. The primary end point was in-hospital Thrombolysis 
In Myocardial Infarction (TIMI)-defined major bleeding; secondary end points were other in-hospital bleeding and vascular complications.
results: Patients in the CP-load were younger, with lower rates of cardiovascular risk factors. Significantly more patients in the CP-load group 
presented with biomarker positive myocardial infarction (80.0 vs. 30.6%, p=<0.001) and cardiogenic shock (5.6 vs. 1.4%, p=0.022). There were no 
significant differences (p=NS) in TIMI major bleeding (2.6 vs. 2.8%), TIMI major or minor bleeding (12.2 vs. 7.0%), need for blood transfusion (2.6 
vs. 2.1%) and vascular complications (1.3 vs. 2.0%) between the CP-load and P-load groups. The C-P load group experienced more in-hospital major 
adverse cardiac events (5.6 vs. 1.6%, p=0.031), urgent coronary artery bypass grafting (3.3 vs. 0.2%, p=0.011) and longer hospital (3.2 vs. 2.4 days, 
p=0.014) and intensive care unit (0.8 vs. 0.3 days, p <0.001) stays.
conclusions: For patients with ACS who are subjected to PCI and were loaded with clopidogrel prior to arrival to the catheterization laboratory, it is 
safe to reload with prasugrel in the catheterization laboratory with respect to in-hospital bleeding and vascular complications. 
